ParaPRO: Innovations in Life Sciences

Welcome to ParaPRO
ParaPRO is a Specialty Pharmaceutical Company created in 2002 to acquire, develop, and commercialize proprietary products in focused high potential markets.

Information on Natroba™ (spinosad) Topical Suspension 0.9%.

Current ParaPRO News!

Newest Head Lice Treatment Now Available to Meet Strong Demand
Natroba™ (spinosad) Topical Suspension, 0.9% Now Available in U.S. Pharmacies

Read the full press release >>

ParaPRO Announces Medicaid Therapeutic Committee Recommendation in Indiana for Natroba™
Read the full press release >>

Pernix Therapeutics Announces Exclusive Co-Promotion Agreement with ParaPRO LLC
Pernix Therapeutics Holdings, Inc., an integrated specialty pharmaceutical company primarily focused on the pediatric market, today announced the execution of an exclusive co-promotion agreement with ParaPRO LLC for a medication to treat head lice (pediculosis capitis) in humans.
Full story/Press Release >>

The American Academy of Pediatrics released their Updated Head Lice Report in the online version of Pediatrics.
Key points include a call to abandon school No Nit Policies , pediatricians are encouraged to take an active role in diagnosis and providing information, diagnosis needs to be confirmed before treatment and treatments should have a clinical record of efficacy and safety for consideration.
Full story/Press Release >>

New Study in the Journal Pediatrics® Reports Results Showing Superior Efficacy of Spinosad Head Lice Treatment as Compared to Permethrin
Full story/Press Release >>

ParaPRO introduces Dr. Itchy™ to help school nurses and parents teach students about head lice.
Free Head Lice Educational Toolkit available at www.dritchy.com includes a Head Lice Educational Poster, Head Lice Pictures, an editable School Nurse Head Lice Notification Letter and “Is It Head Lice?” presentation with kid-friendly instruction to reduce the stigma of a head lice infestation.
Full story/Press Release >>

Current Head Lice News
American Academy of Pediatrics (AAP) policy on treating head lice
Full story >>




Ask your doctor if Natroba Topical Suspension is right for you or your child.

INDICATION
Natroba Topical Suspension is a pediculicide indicated for the topical treatment of head lice infestations in patients four (4) years of age and older.

ADJUNCTIVE MEASURES
Natroba TM Topical Suspension should be used in the context of an overall lice management program:
  • Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
  • Wash personal care items such as combs, brushes, and hair clips in hot water
A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

IMPORTANT SAFETY INFORMATION
Natroba Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants.

Most common adverse events were: application site redness (3%), redness and irritation of the eyes (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.